Model 1 | Model 2 | |||||
---|---|---|---|---|---|---|
Unadjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
All-cause mortality (n = 171) | ||||||
sST2 (per twofold increase) | 1.31 (1.05–1.63) | 0.016 | 1.36 (1.05–1.76) | 0.018 | 1.33 (1.06–1.67)a | 0.014 |
sST2 ≥ 35 ng/ml | 1.41 (1.04–1.90) | 0.025 | 1.45 (1.03–2.04) | 0.035 | 1.36 (1.00–1.85)a | 0.049 |
sST2 ≥ 33 ng/ml (optimal) | 1.52 (1.12–2.05) | 0.007 | 1.62 (1.15–2.29) | 0.006 | 1.46 (1.07–1.99)a | 0.016 |
Cardiovascular mortality (n = 62) | ||||||
sST2 (per twofold increase) | 1.50 (1.05–2.13) | 0.024 | 1.65 (1.09–2.48) | 0.017 | 1.50 (1.03–2.18)a | 0.033 |
sST2 ≥ 35 ng/ml | 1.31 (0.80–2.16) | 0.288 | 1.43 (0.80–2.56) | 0.233 | 1.16 (0.69–1.94)a | 0.576 |
sST2 ≥ 41 ng/ml (optimal) | 1.72 (1.04–2.85) | 0.035 | 1.90 (1.06–3.43) | 0.032 | 1.57 (0.93–2.67)a | 0.092 |
MACE (n = 131) | ||||||
sST2 (per twofold increase) | 1.36 (1.07–1.74) | 0.013 | 1.30 (0.97–1.73) | 0.079 | 1.40 (1.08–1.80)b | 0.010 |
sST2 ≥ 35 ng/ml | 1.34 (0.95–1.88) | 0.096 | 1.09 (0.74–1.63) | 0.659 | 1.19 (0.84–1.71)b | 0.332 |
sST2 ≥ 24 ng/ml (optimal) | 1.75 (1.09–2.82) | 0.021 | 1.70 (0.97–3.01) | 0.066 | 1.89 (1.14–3.13)b | 0.013 |